Page 4 - Nucleus Network News Today

/PRNewswire/ -- Inhalon Biopharma, Inc., a clinical-stage immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating acute...

Australian medical research house Burnet Institute has secured a giant payday for its clinical research testing spin-off, 360biolabs, 

New model could help test vaccines against the deadly Strep A bacteria Researchers have successfully developed a new Strep A human challenge model, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores. The collaborative research effort, led by the Murdoch Childrens Research Institute (MCRI) and published in The Lancet Microbe, found the model, which deliberately infected healthy adult volunteers with the bacteria in a control...

A leading Australian infectious diseases and vaccine expert has answered some of the growing questions about the countrys vaccine rollout, including the topic of choosing between AstraZeneca and Pfizer. 9News talked with Associate Professor Paul Griffin, who has worked on COVIDs frontline at the Mater Hospital in Brisbane. He has overseen more than 100 clinical trials of vaccine as a part of the Nucleus Network. READ MORE: 9News sat down with Associate Professor Paul Griffin, who has worked on ...

Researchers have successfully developed a new Strep A human challenge model, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores.

Murdoch Childrens Research Institute Researchers have successfully developed a new Strep A human challenge model, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores. The collaborative research effort, led by the Murdoch Children’s Research Institute (MCRI) and published in The Lancet Microbe, found the model, which deliberately infected healthy adult volunteers with the bacteria in a controlled environment, was safe and wo...

Health by Tiffany Bakker Premium Content   Were on a first-name basis with the AstraZeneca vaccine and we know all about Pfizer and, if you have family overseas, chances are youve heard about Moderna and Johnson & Johnson. But how many new COVID-19 vaccines are in development, when will they be ready for use and just how will we take them?   HOW MANY COVID VACCINES ARE IN DEVELOPMENT? According to the World Health Organisation, there are currently 27...

Health by Tiffany Bakker Premium Content   Were on a first-name basis with the AstraZeneca vaccine and we know all about Pfizer and, if you have family overseas, chances are youve heard about Moderna and Johnson & Johnson. But how many new COVID-19 vaccines are in development, when will they be ready for use and just how will we take them?   HOW MANY COVID VACCINES ARE IN DEVELOPMENT? According to the World Health Organisation, there are currently 27...

Lazard, Allens test interest in Aussie lab services play 360Biolabs Save Share Australian laboratory services provider 360Biolabs is seeking to capitalise on red-hot demand for biotech research testing companies and their service providers. 360Biolabs provides laboratory services to clinical research organisations, helping to test and develop the next wave of therapeutics, vaccinations and diagnostic tools.  Stuart Layt Street Talk can reveal 360Biolabs, which is based in Melbourne and makes...

Last modified on Thu 22 Apr 2021 23.01 EDT Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray. Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation. The trial from June to September proposes using genetic modification to prevent t...